Scott Levenson, MD
Gastroenterology · San Carlos, CANPI 1578548186
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $96,098 of the $132,537 with a category attached, or 72.5%. 40 manufacturers reported payments, led by AbbVie at 34.9% of the total. Reporting peaked in 2024 at $56,800 and has fallen 66.8% since, to $18,846 in 2025. Among gastroenterology clinicians in CA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 1,411 payments — averaging $93.93 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$46K
- Phathom Pharmaceuticals, Inc.$43K
- Aimmune Therapeutics, Inc.$11K
- Nestle Healthcare Nutrition Inc.$6K
- QOL Medical, LLC$6K
- Takeda Pharmaceuticals U.S.A., Inc.$2K
- plus $18K from 34 others
Across 62 payments — averaging $3893.12 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Ironwood Pharmaceuticals, Inc$163K
- Roche Products Limited$39K
- AbbVie$16K
- Redhill Biopharma Inc.$15K
- Otsuka Pharmaceutical Development & Commercialization, Inc.$8K
What the payments were for
- Consulting fees$4,4403%
- Speaking & faculty fees$96,09873%
- Travel & lodging$5,5534%
- Food & beverage$26,26620%
- Education$1810%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$132,537 in reported general payments places this provider in the 95th percentile of 1,885 gastroenterology providers in California.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| CreonLipase/Protease/Amylase | 61 | $210,023 |
| LinzessLinaclotide | 69 | $95,917 |
| ZenpepLipase/Protease/Amylase | 14 | $39,756 |
| ViberziEluxadoline | 11 | $18,800 |
| TrulancePlecanatide | 19 | $15,438 |
| MotegrityPrucalopride Succinate | 17 | $9,580 |
| Dexlansoprazole DrDexlansoprazole | 34 | $8,485 |
| MovantikNaloxegol Oxalate | 15 | $5,838 |
| Sucralfate | 17 | $5,401 |
| Sod Sulf-Potass Sulf-Mag SulfSodium, Potassium,mag Sulfates | 80 | $5,250 |
| Pantoprazole Sodium | 171 | $4,531 |
| Omeprazole | 172 | $3,425 |
| Lansoprazole | 38 | $2,302 |
| Esomeprazole Magnesium | 43 | $2,121 |
| Lubiprostone | 12 | $2,096 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AbbVieCreon, Linzess, Viberzi | $46,247 | $324,740141 claims |
| Aimmune Therapeutics, Inc.Zenpep | $10,844 | $39,75614 claims |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLCTrulance | $2,204 | $15,43819 claims |
| Takeda Pharmaceuticals U.S.A., Inc.Motegrity | $2,278 | $9,58017 claims |
| Redhill Biopharma Inc.Movantik | $2,069 | $5,83815 claims |
| SandozLansoprazole | $23 | $2,30238 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 1,885 gastroenterology providers in California.
Other gastroenterology in San Carlos
- Bennett RothLos Angeles$2.8M
- Douglas NguyenMission Viejo$2M
- Sammy SaabLos Angeles$1.9M
- Kenneth ChangNewport Beach$1.3M
- Joo HwangStanford$1M
- Drew SchembreWalnut Creek$659K
- Quan Nhula Jolla$641K
- Sadeea AbbasiLos Angeles$556K
- Ali RezaieWest Hollywood$519K
- Kenneth BinmoellerSan Francisco$507K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.